Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

Authors :: Jimenez, MM
Zielinski, C
Ruiz-Borrego, M
Carrasco, E
Ciruelos, EM
Munoz, M
Bermejo, B
Margeli, M
Csoszi, T
Anton, A
Turner, N
Casas, MI
Morales, S
Alba, E
Calvo, L
De la Haba, J
Ramos, M
Corsaro, M
Kahan, Z
Gil-Gil, M
Source :: Annals of Oncology, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Publication Year :: 2021
Publisher :: Oxford University Press, 2021.

ISSN :: 09237534
Database :: OpenAIRE
Journal :: Annals of Oncology, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Accession number :: edsair.RECOLECTA.....0fee28c3aef451538129fd7d7918a35a

Tools